Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals

Early Stage

A clinical-stage biotechnology company

A clinical-stage biotechnology company

Overview

Raised to Date: Raised: $43,249,314

Total Commitments ($USD)

Platform

Dalmore Group

Start Date

04/29/2020

Close Date

Not Provided

Min. Goal
$4,000
Max. Goal
$50,000,000
Min. Investment

$4,000

Security Type

Equity - Common

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$8.00

Rolling Commitments ($USD)

Status
Funded
Reporting Date

03/30/2021

% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$129,102

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Location

San Diego, California

Emerald Health Pharmaceuticals is raising funds on Dalmore Group through Reg A+ crowdfunding. It is a pharmaceutical company focused on developing its drug product candidates, EHP-101 and EHP-102. The drug candidates of Emerald Health Pharmaceuticals target multiple sclerosis, systemic sclerosis, Parkinson’s disease, and Huntington’s disease. Emerald Health Pharmaceuticals has a unique technological advantage as its patented molecules, NCEs, are based on CBD and CBG molecular architectures. James M. DeMesa founded Emerald Health Pharmaceuticals in 2017. The current crowdfunding campaign has no minimum target and a maximum target of $50,000,000. The campaign proceeds will be used for clinical studies, research and development, and general and administrative expenses.

Balance Sheet

Cash and Cash Equivalents

$17,036,840

Accounts and Notes Receivable

$513,953

Property, Plant and Equipment (PP&E)

$35,068

Total Assets

$21,092,332

Accounts Payable & Accrued Liabilities

$2,771,443

Total Liabilities

$8,441,635

Total Stockholders' Equity

$12,358,545

Total Liabilities and Equity

$21,092,332

Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev

$11,961,268

Depreciation and Amortization

$24,596

Net Income

$-12,424,622

Earnings Per Share - Basic

$-0.77

Earnings Per Share - Diluted

$-0.77

Auditor: Deloitte & Touche LLP
Financials as of: 04/29/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Emerald Health Pharmaceuticals 07/07/2021 Self Managed - $300,000 Equity - Common Funded RegD 506(b)
Emerald Health Pharmaceuticals 03/30/2021 Dalmore Group - $43,249,314 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Emerald Health Pharmaceuticals on Dalmore Group 2021
Platform: Dalmore Group
Security Type: Equity - Common
Price per Share: $8.00

Follow company

Follow Emerald Health Pharmaceuticals on Dalmore Group 2021

Buy Emerald Health Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Emerald Health Pharmaceuticals may no longer be accepting investments.

Emerald Health Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Emerald Health Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Emerald Health Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Emerald Health Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge